Isofol Medical: First patient enrolled in phase III trial

Research Note

2018-12-18

17:04

Isofol Medical took a major step forward today, announcing that the first patient has been enrolled in the phase III trial AGENT, studying arfolitixorin in metastatic colorectal cancer (mCRC). We believe that the share price reaction was too modest and argue that the current share price reflects a valuation far from the fundamental value. We will return with an updated analysis shortly.

AN

Arvid Necander

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.